Detalhe da pesquisa
1.
CD19-CD28: An affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437725
2.
CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.
Front Oncol
; 13: 1150149, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37205201
3.
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Clin Cancer Res
; 28(4): 770-780, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782366
4.
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Cancer Res
; 82(14): 2552-2564, 2022 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35584009
5.
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
Elife
; 102021 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378534
6.
The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.
Front Immunol
; 11: 2082, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33013879
7.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Nat Commun
; 11(1): 3196, 2020 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32581215
8.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Nat Cancer
; 1(12): 1153-1166, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33644766
9.
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Leukemia
; 38(2): 398-402, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38212534